Publication: 3554

Publication: 3554

Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302)

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 39 (no. 15_suppl) 6076

Meeting Instance:: ASCO 2021
Year:: 2021
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 4157

Program:: OGC
Primary Committee:: Experimental
Sec. Committees:

Pharmas:: Novartis/GSK
Grants:: U10CA180821, U10CA180882

Corr. Author:
Authors:: Eric Sherman Nathan R. Foster Yungpo Bernard Su Ardaman Shergill Alan Ho Bhavana Konda Ronald A. Ghossein Ian Ganly Gary K. Schwartz

Networks:: COLUMBIA, LAPS-IL057, LAPS-MN026, LAPS-NY016, LAPS-OH007, NE003

Study: Alliance-A091302
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: